文献速递核素与放射性配体治疗肿瘤 PET/CT

225Ac-PSMA-617放射性配体治疗新发转移性激素敏感性前列腺癌(mHSPC)的初步临床发现

225Ac-PSMA-617 radioligand therapy of de novo metastatic hormone-sensitive prostate carcinoma (mHSPC): preliminary clinical findings.
PubMed 文献 · Eur J Nucl Med Mol Imaging · 2023-03-03

该回顾性系列纳入21例拒绝标准治疗的新发转移性激素敏感性前列腺癌(mHSPC)患者,接受225Ac-PSMA-617放射性配体治疗。20例(95%)PSA任何程度下降,18例(86%)PSA下降≥50%包括4例PSA不可测;PSA下降百分比较低与死亡率增加和无进展生存期缩短相关;最常见毒性为1/2级口干(94%)。作者认为鉴于结果良好,随机前瞻性多中心试验评估225Ac-PSMA-617单药或联合ADT治疗mHSPC的临床价值值得关注。

要点

  • 21例拒绝标准治疗的新发mHSPC患者接受225Ac-PSMA-617,20例(95%)PSA任何程度下降,18例(86%)PSA下降≥50%。
  • 4例患者PSA变为不可测;PSA下降百分比较低与死亡率增加及无进展生存期缩短相关。
  • 最常见毒性为1/2级口干,见于94%患者;总体耐受良好。

核心结论

  • 作者认为鉴于这些良好结果,评估225Ac-PSMA-617作为mHSPC治疗药物(单药或联合ADT给药)临床价值的随机前瞻性多中心试验值得关注。

研究设计与样本

  • 回顾性系列纳入21例经组织学确诊的新发初治骨±内脏mHSPC患者,均拒绝标准治疗并接受225Ac-PSMA-617放射性配体治疗。
  • 纳入标准包括ECOG体能状态0至2、初治骨±内脏mHSPC、患者拒绝ADT±多西他赛、醋酸阿比特龙或恩扎卢胺。
  • 评估指标为PSA应答、无进展生存期(PFS)、总生存期(OS)及毒性。

主要发现

  • 治疗后20例(95%)患者PSA任何程度下降,18例(86%)患者PSA下降≥50%,其中4例患者PSA变为不可测。
  • 治疗后PSA下降百分比较低与死亡率增加和无进展生存期缩短相关。
  • 225Ac-PSMA-617总体耐受良好,最常见毒性为1/2级口干,见于94%患者。

局限性

  • 原文为回顾性系列,仅21例患者,作者称其为初步工作(preliminary work)。
  • 作者在结论中指出需随机前瞻性多中心试验评估225Ac-PSMA-617在mHSPC中的临床价值。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

PURPOSE: 225Ac-PSMA-617 has demonstrated good anti-tumor effect as a treatment option for metastatic castration-resistant prostate cancer (mCRPC) patients. No study has previously assessed treatment outcome and survival following 225Ac-PSMA-617 treatment of de novo metastatic hormone-sensitive prostate carcinoma (mHSPC) patients. Based on the potential side effects that are known and explained to the patients by the oncologist, some of the patients refused the standard treatment and are seeking alternative therapies. Thus, we report our preliminary findings in a retrospective series of 21 mHSPC patients that refused standard treatment options and were treated with 225Ac-PSMA-617. METHODS: We retrospectively reviewed patients with histologically confirmed de novo treatment-naïve bone ± visceral mHSPC that were treated with 225Ac-PSMA-617 radioligand therapy (RLT). Inclusion criteria included an Eastern Cooperative Oncology Group (ECOG) performance status of 0 to 2, treatment-naive bone ± visceral mHSPC, and patients refusal for ADT ± docetaxel, abiraterone acetate, or enzalutamide. We evaluated the response to treatment using prostate-specific antigen (PSA) response and the progression-free survival (PFS) and overall survival (OS) as well as the toxicities. RESULTS: Twenty-one mHSPC patients were included in this preliminary work. Following treatment, twenty patients (95%) had any decline in PSA and eighteen patients (86%) presented with a PSA decline of ≥ 50% including 4 patients in whom PSA became undetectable. A lower percentage decrease in PSA following treatment was associated with increased mortality and shorter progression-free survival. Overall, administration of 225Ac-PSMA-617 was well tolerated. The commonest toxicity seen was grade I/II dry mouth observed in 94% of patients. CONCLUSIONS: Given these favorable results, randomized prospective multicenter trials assessing the clinical value of 225Ac-PSMA-617 as a therapeutic agent for mHSPC administered either as monotherapy or administered concomitant with ADT are of interest.

来源:Eur J Nucl Med Mol Imaging,查看原文。版权归原作者所有。

引用

  1. Sathekge M, Bruchertseifer F, Vorster M, et al. 225Ac-PSMA-617 radioligand therapy of de novo metastatic hormone-sensitive prostate carcinoma (mHSPC): preliminary clinical findings. Eur J Nucl Med Mol Imaging. 2023. PMID: 36864360. doi:10.1007/s00259-023-06165-9

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。